Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
暂无分享,去创建一个
G. Morgan | W. Gregory | M. Drayson | N. Russell | J. Snowden | M. Jenner | F. Davies | G. Cook | G. Jackson | D. Cairns | R. de Tute | M. Kaiser | R. Owen | M. Garg | C. Pawlyn | J. Lindsay | K. Karunanithi | John R. Jones | A. Hockaday | A. Rocci | B. Kishore | C. Williams | C. Collett